AstraZeneca Pharmaceuticals LP
950 Wind River Lane
About AstraZeneca Pharmaceuticals LP
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
CEO: Pascal Soriot
CFO: Marc Dunoyer
CMO: Marc Dunoyer
CTO: Andrew Chen
CCO: Katarina Ageborg
CMO: Sean Bohen
Please click here for clinical trial information.
Please click here for AstraZeneca job opportunities.
For more information, visit
www.astrazeneca.com and follow us on www.twitter.com/astrazeneca.
Tweets by AstraZeneca
What Science Can Do
1904 articles with AstraZeneca Pharmaceuticals LP
Akero Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $65 million Series A financing round.
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
Boston-based Emulate closed on a Series C round worth $36 million.
Reportedly, Madrigal Pharmaceuticals is considering a sale. After receiving interest from other big drug companies, the nine-employee company is evaluating its options.
Independent data monitoring committee advises lanabecestat is unlikely to meet primary endpoints, leading to decision to discontinue these trials
The prevalence of nonalcoholic steatohepatitis (NASH) is increasing across the globe and is expected to be the leading indication for liver transplants by 2020. Despite that, awareness of the disease is somewhat low.
Yet another drug for Alzheimer’s has been tossed in the trash. AstraZeneca and Eli Lilly announced they have abandoned two late-stage clinical trials of lanabecestat for Alzheimer’s disease.
The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma's internal CNS pipeline.
BioMarin Pharmaceutical received $20 million in milestone payments from Pfizer after the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved its applications for talazoparib.
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors
Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.
Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results
Advaxis, Inc. today announced a new prioritization of its product portfolio, as well as financial results and business highlights for the three months ended April 30, 2018.
DiviTum results from a large AstraZeneca study are presented today at the ASCO meeting in Chicago, the largest cancer congress in the world.
LYNPARZA® (olaparib) in Combination with Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer
AstraZeneca and Merck presented data which showed clinical improvement in median radiologic progression-free survival (rPFS) with LYNPARZA® (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a current standard of care, in metastatic castration-resistant prostate cancer (mCRPC).
Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).
AstraZeneca’s add-on asthma treatment Fasenra has failed a second Phase III trial this month.
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential treatments for a disease that has no approved therapies in the United States.
IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer
IMFINZI met the second primary endpoint of overall survival which was both statistically significant and clinically meaningful at a planned interim analysis
AstraZeneca and its research-and-development unit MedImmune, announced positive overall survival (OS) data for its Phase III PACIFIC trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC).
Brii Biosciences Launches with $260 Million, a Partnership with Vir Biotech, and Other Relationsh...
5/24/2018Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.
New programs added in respiratory and cardio-metabolic diseases